Enasidenib mesylate
CAS No. 1650550-25-6
Enasidenib mesylate ( —— )
产品货号. M33941 CAS No. 1650550-25-6
Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥323 | 有现货 |
|
| 10MG | ¥517 | 有现货 |
|
| 25MG | ¥696 | 有现货 |
|
| 50MG | ¥884 | 有现货 |
|
| 100MG | ¥1125 | 有现货 |
|
| 500MG | ¥2815 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Enasidenib mesylate
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Enasidenib mesylate 是一种有效的,可口服的,可逆的,选择性的 IDH2 突变酶抑制剂。
-
产品描述Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
-
体外实验Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2 wks.
-
体内实验Treatment with enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10 mg/kg or 100 mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100 mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate (2-HG) levels consistent with on target inhibition. Enasidenib inhibits mutant IDH2-mediated 2-HG production.
-
同义词——
-
通路Metabolic Enzyme/Protease
-
靶点Dehydrogenase
-
受体Dehydrogenase
-
研究领域——
-
适应症——
化学信息
-
CAS Number1650550-25-6
-
分子量569.48
-
分子式C20H21F6N7O4S
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : ≥ 100 mg/mL (175.60 mM )
-
SMILESCS(O)(=O)=O.CC(C)(O)CNc1nc(Nc2ccnc(c2)C(F)(F)F)nc(n1)-c1cccc(n1)C(F)(F)F
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015
产品手册
关联产品
-
CP-642931
Sorbitol dehydrogenase-IN-1 是一种有效的具有口服活性的山梨醇脱氢酶 sorbitol dehydrogenase 抑制剂,对大鼠和人类的 IC50 s 值分别为 4、5 nM。
-
KS100
KS100 是一种有效的 ALDH 抑制剂,对 ALDH1A1、ALDH2 和 ALDH3A1 的 IC50 分别为 334、2137、360 nM。KS100 具有低毒性的抗增殖和抗癌作用。KS100 显著增加 ROS 活性、脂质过氧化和有毒醛的积累。KS100 诱导细胞凋亡 (apoptosis) 和细胞周期停滞在 G2/M 期。
-
LDH-IN-1
LDH-IN-1 是一种新型吡唑类人乳酸脱氢酶 (LDH) 抑制剂,对 LDHA 和 LDHB 的 IC50 值分别为 32 和 27 nM。 LDH-IN-1 抑制 MiaPaCa2 胰腺癌和 A673 肉瘤细胞的生长,IC50 分别为 2.23 和 1.21 μM。
021-51111890
购物车()
sales@molnova.cn

